

## CERTIFICATE

DIRECTIVE 98/79/EC  
EC DESIGN-EXAMINATION

CeCert Sp. z o.o. hereby confirms that manufactured by

**Shenzhen Microprofit Biotech Co., Ltd.**

Rm. 405, 406, Zone B/4F, Rm. 205, 206-1, 207, West Side  
of Zone B/ 2F, Haowei Building, No. 8 Langshan 2nd  
Road, Songpingshan, Songpingshan Community,  
Xili Street, Nanshan District, Shenzhen, P.R. China

*in vitro* diagnostic medical device for self-testing

**fluorecare SARS-CoV-2 & Influenza A/B  
& RSV Antigen Combo Test Kit**

catalogue numbers: MF-71-1, MF-71-2, MF-71-5

in term of the design conforms to the requirements of Annex III  
section 6 to Directive 98/79/EC (as amended) implemented into Polish  
Law, as evidenced by the assessment conducted  
by CeCert Sp. z o.o.



**2934**

Validity date: 12.05.2022 – 26.05.2025

Edition issue date: 18.05.2022

Check it



CeCert Sp. z o.o.  
ul. Żurawia 32/34  
00-515 Warszawa

www.cecert.pl  
e-mail: [biuro@cecert.pl](mailto:biuro@cecert.pl)

Kamil Szczurowski  
Director of *in Vitro* Diagnostic Medical Device  
Certification Department

Certificate no: [CeCert/092/W/E.2](#)